Afficher la notice abrégée

Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen

dc.rights.licenseopenen_US
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBARRY, Houreratou
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLHOMME, Edouard
dc.contributor.authorSURENAUD, Mathieu
dc.contributor.authorNOUCTARA, Moumini
dc.contributor.authorROBINSON, Cynthia
dc.contributor.authorBOCKSTAL, Viki
dc.contributor.authorVALEA, Innocent
dc.contributor.authorSOMDA, Serge
dc.contributor.authorTINTO, Halidou
dc.contributor.authorMEDA, Nicolas
dc.contributor.authorGREENWOOD, Brian
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTHIEBAUT, Rodolphe
dc.contributor.authorLACABARATZ, Christine
dc.date.accessioned2024-06-13T14:27:11Z
dc.date.available2024-06-13T14:27:11Z
dc.date.issued2024-04-11
dc.identifier.issn1935-2735en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/200467
dc.description.abstractEnBACKGROUND: The exposure to parasites may influence the immune response to vaccines in endemic African countries. In this study, we aimed to assess the association between helminth exposure to the most prevalent parasitic infections, schistosomiasis, soil transmitted helminths infection and filariasis, and the Ebola virus glycoprotein (EBOV GP) antibody concentration in response to vaccination with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in African and European participants using samples obtained from three international clinical trials. METHODS/PRINCIPAL FINDINGS: We conducted a study in a subset of participants in the EBL2001, EBL2002 and EBL3001 clinical trials that evaluated the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against EVD in children, adolescents and adults from the United Kingdom, France, Burkina Faso, Cote d'Ivoire, Kenya, Uganda and Sierra Leone. Immune markers of helminth exposure at baseline were evaluated by ELISA with three commercial kits which detect IgG antibodies against schistosome, filarial and Strongyloides antigens. Luminex technology was used to measure inflammatory and activation markers, and Th1/Th2/Th17 cytokines at baseline. The association between binding IgG antibodies specific to EBOV GP (measured on day 21 post-dose 2 and on Day 365 after the first dose respectively), and helminth exposure at baseline was evaluated using a multivariable linear regression model adjusted for age and study group. Seventy-eight (21.3%) of the 367 participants included in the study had at least one helminth positive ELISA test at baseline, with differences of prevalence between studies and an increased prevalence with age. The most frequently detected antibodies were those to Schistosoma mansoni (10.9%), followed by Acanthocheilonema viteae (9%) and then Strongyloides ratti (7.9%). Among the 41 immunological analytes tested, five were significantly (p < .003) lower in participants with at least one positive helminth ELISA test result: CCL2/MCP1, FGFbasic, IL-7, IL-13 and CCL11/Eotaxin compared to participants with negative helminth ELISA tests. No significant association was found with EBOV-GP specific antibody concentration at 21 days post-dose 2, or at 365 days post-dose 1, adjusted for age group, study, and the presence of any helminth antibodies at baseline. CONCLUSIONS/SIGNIFICANCE: No clear association was found between immune markers of helminth exposure as measured by ELISA and post-vaccination response to the Ebola Ad26.ZEBOV/ MVA-BN-Filo vaccine regimen. TRIAL REGISTRATION: NCT02416453, NCT02564523, NCT02509494. ClinicalTrials.gov.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.title.enHelminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen
dc.title.alternativePLoS Negl Trop Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1371/journal.pntd.0011500en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed38603720en_US
dc.description.sponsorshipEuropeDevelopment of a prophylactic Ebola vaccine using an heterologous prime-boost regimen: phase IIen_US
bordeaux.journalPLoS Neglected Tropical Diseasesen_US
bordeaux.pagee0011500en_US
bordeaux.volume18en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue4en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionINRIAen_US
bordeaux.teamSISTM_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDInnovative Medicines Initiativeen_US
hal.identifierhal-04611372
hal.version1
hal.date.transferred2024-06-13T14:27:14Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=PLoS%20Neglected%20Tropical%20Diseases&amp;rft.date=2024-04-11&amp;rft.volume=18&amp;rft.issue=4&amp;rft.spage=e0011500&amp;rft.epage=e0011500&amp;rft.eissn=1935-2735&amp;rft.issn=1935-2735&amp;rft.au=BARRY,%20Houreratou&amp;LHOMME,%20Edouard&amp;SURENAUD,%20Mathieu&amp;NOUCTARA,%20Moumini&amp;ROBINSON,%20Cynthia&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_PLoSNeglTropDis_2024_Barry.pdf
Taille:
552.6Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée